3 Quantum Computing Stocks That Could Help Make You a Fortune

Three quantum-computing vendors—Rigetti, IonQ and QCi—are presented with 2024 revenues of $10.8M, $43.1M and $0.4M, respectively, and 2027 revenue estimates of $45.8M (Rigetti, 3‑yr CAGR 62%), $316.5M (IonQ, 94% CAGR) and $15.0M (QCi, 235% CAGR). All three trade at very high 2027 revenue multiples (Rigetti 161x, IonQ 52x, QCi 159x) but, under an optimistic scenario of 30% CAGR from 2027 to 2035, could imply 2035 market caps of ~$11.2B, $77.4B and $3.7B respectively. The piece underscores differing technical approaches (superconducting electrons, trapped ions, photonics), product road maps and operational tradeoffs, while flagging these names as speculative, volatile, and dependent on execution against aggressive growth assumptions.

Analysis

Market structure: IonQ (IONQ) and photonics vendors (QUBT) are the most direct near-term beneficiaries — IonQ from higher gate fidelity and government contracts, QUBT from fabs' ability to mass-produce TFLN chips and lower OPEX. Rigetti (RGTI) and other superconducting players face higher operating costs (cryogenics) and more competition from IBM/Google; pricing power will be limited unless one tech achieves clear superiority. Expect early-stage demand to be driven by cloud contracts and gov spend, not enterprise capex, keeping unit volumes low and volatility high for 12–36 months.

Risk assessment: Key tail risks include a failed Dirac-3 launch or a major fidelity setback (operational risk), cross-border export controls on quantum hardware (regulatory), and dilutive equity raises (financial). Near term (days–months) volatility will spike around product announcements and contract wins; medium/long term (1–5 years) risks center on commoditization of photonic chips and consolidation. Hidden dependencies: dependence on fabs (for QUBT), cryo supply chains (RGTI), and human calibration expertise (IONQ) — each can bottleneck scale.

Trade implications: Tactical long bias to IONQ with protective hedges is preferred; QUBT is a high upside, low-probability structural bet ahead of Dirac-3 validation. Prefer pair trades (long IONQ, short RGTI) to exploit relative fundamentals and valuations (IONQ trading at ~52x 2027 sales vs RGTI ~161x). Options: use 6–18 month call spreads to cap premium on longs and buy puts to limit downside in small-cap quantum names.

Contrarian angles: Consensus underprices photonics’ potential to commoditize QPU hardware within 3–6 years — if Dirac-3 proves manufacturable, margin compression will force consolidation, benefiting fabs and cloud incumbents (IBM, GOOG). Conversely, market may be overpaying for near-term revenue growth; avoid full-price long exposure until post-launch performance data or reproducible gate-fidelity improvements are public.

Key Decisions for Investors

• Establish a 2% NAV long position in IONQ (NYSE: IONQ) over 12–24 months, target ~100% upside on successful contract/guide beats; hedge with 6–9 month puts 20–30% OTM sized at 50% of the long notional and set a stop-loss at -30%.
• Implement a dollar-neutral pair trade: long IONQ 1.5% NAV vs short RGTI 1.5% NAV (target relative outperformance 30–50% within 6–12 months); close or rebalance if RGTI revenue guidance is met and IONQ misses, or if either stock moves >40% intraday from entry.
• Speculative directional: allocate 0.5–1% NAV to QUBT via 18–24 month LEAP call spreads (buy calls, sell higher strike) ahead of the Dirac-3 launch; cap downside to this allocation and take profits if shares rally >150% or if Dirac-3 fails initial benchmarks.
• Reallocate 3–5% from small-cap speculative quantum exposure into large-cap, less-correlated beneficiaries: add 2% NVDA for accelerated classical-quantum workloads and 1–2% IBM (quantum services + enterprise clients); reassess after next two quarters of product/earnings prints.